Agenus’ Post

View organization page for Agenus, graphic

37,677 followers

1mo

Results from our Phase 1 clinical trial have been published in Nature Portfolio's Nature Medicine. This publication highlights the potential of our novel immunotherapy combination, botensilimab plus balstilimab, for treating microsatellite stable metastatic colorectal cancer (MSS mCRC), a cancer type historically resistant to immunotherapy. Read the full publication here: https://lnkd.in/ernW76JY

6 Comments

OncoDaily

1mo

We would like to inform you that your post has been successfully published on Oncodaily. Thank you for sharing such valuable content. https://oncodaily.com/insight/83862.html

Ollie Scott MSc

1mo

Wonderful work! massive congratulations to the incredible and amazing people involved in this research. 😀

Justin Stebbing

Editor-in-Chief of Oncogene, Professor of Biomedical Sciences, ARU, Cambridge, Visiting Professor of Oncology, Imperial College, London, Phoenix Hospital Group, VP Graviton

1mo

congratulations

Chinese Antibody Society

1mo

Congratulations!

Graham Cross

NED/Consultant to IFAs

Sounds incredible Tony. Great news.

Linda Noa

Retired from Mallinckrodt Pharmaceuticals

Awesome!

See more comments

To view or add a comment, sign in

More Relevant Posts

Breast Cancer Trials

3,370 followers
2mo
Report this post
The CAPTURE clinical trial is open to women and men with ER positive, HER2 negative breast cancer, that has returned after treatment with a CDK4/6 inhibitor. CAPTURE is looking at individuals who have become resistant to their endocrine (hormone) therapy, and seeing if this can be overcome with new targeted therapies. "If this treatment option is effective, we would hope that we would be able to prolong the lives of individuals who have this type of breast cancer." - Study Chair, Professor Sarah-Jane Dawson. Learn more about this clinical trial here: https://lnkd.in/gMgmirw

The CAPTURE Clinical Trial
Like Comment
To view or add a comment, sign in
Breast Cancer Trials

3,370 followers
9mo
Report this post
The CAPTURE clinical trial is open to women and men with ER positive, HER2 negative breast cancer, that has returned after treatment with a CDK4/6 inhibitor. CAPTURE is looking at individuals who have become resistant to their endocrine (hormone) therapy, and seeing if this can be overcome with new targeted therapies. "If this treatment option is effective, we would hope that we would be able to prolong the lives of individuals who have this type of breast cancer." - Study Chair, Professor Sarah-Jane Dawson. Learn more about this clinical trial here: https://lnkd.in/gMgmirw

The CAPTURE Clinical Trial
Like Comment
To view or add a comment, sign in
Breast Cancer Trials

3,370 followers
1w
Report this post
The CAPTURE clinical trial is open to women and men with ER positive, HER2 negative breast cancer, that has returned after treatment with a CDK4/6 inhibitor. CAPTURE is looking at individuals who have become resistant to their endocrine (hormone) therapy, and seeing if this can be overcome with new targeted therapies. "If this treatment option is effective, we would hope that we would be able to prolong the lives of individuals who have this type of breast cancer." - Study Chair, Professor Sarah-Jane Dawson. Learn more about this clinical trial here: https://lnkd.in/gMgmirw
Like Comment
To view or add a comment, sign in
Biomedicines MDPI

1,786 followers
11mo
Report this post
#HighlyCitedPapers 🔬 Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies, by Sneha et al. The purpose of this #review was to provide an update on how the presence of #cytochrome P450 impacts on standard of care drugs used to treat breast #cancer as well as discuss opportunities to exploit CYP expression for therapeutic intervention. 👀 https://lnkd.in/eitt5g65 #breastcancer #breast_cancer
Like Comment
To view or add a comment, sign in
OncoDaily

18,715 followers
3mo
Report this post
Some guidance on the management of adverse events with sotorasib in KRAS G12C NSCLC Lung Cancer Journal - Stephen Liu MedStar Georgetown University Hospital https://lnkd.in/dP_7-FKb #Cancer #LungCancer #NSCLC #OncoDaily #Oncology #CancerResearch #CancerTherapy

Stephen V Liu: Some guidance on the management of adverse events with sotorasib in KRAS G12C NSCLC Lung Cancer Journal - OncoDaily

oncodaily.com
Like Comment
To view or add a comment, sign in
Breast Cancer Trials

3,370 followers
6mo
Report this post
The CAPTURE clinical trial is open to women and men with ER-positive, HER2-negative breast cancer, that has returned after treatment with a CDK4/6 inhibitor. CAPTURE is looking at individuals who have become resistant to their endocrine (hormone) therapy, and seeing if this can be overcome with new targeted therapies. "If this treatment option is effective, we would hope that we would be able to prolong the lives of individuals who have this type of breast cancer." - Study Chair, Professor Sarah-Jane Dawson. Learn more about this clinical trial here: https://lnkd.in/gMgmirw

The CAPTURE Clinical Trial
Like Comment
To view or add a comment, sign in
Cyrus Chargari

Chef du Service d'Oncologie Radiothérapie, Hôpital Universitaire Pitié Salpetrière -Sorbonne Université
1w
Report this post
Theragnostic approaches in cervical cancer treatment. A path for improving treatment efficacy and personalized strategies
NH TherAguix

1,449 followers
1w

NH TherAguix Announces the Publication of Groundbreaking Study on AGuIX® Nanoparticles Enhancing Cervical Cancer Treatment!! 🧬 Key clinical milestone showcasing the potential of AGuIX®, a next-generation nanodrug developed by NH TherAguix to improve tumor targeting and augment efficacy when combined with chemoradiation and brachytherapy. 💊 Phase I clinical trial results demonstrate safety, tolerance, and promising therapeutic outcomes in locally advanced cervical cancer patients. If you want to know more, read the press release: https://lnkd.in/ezK9RpXq #NHTherAguix #AGuIX #CervicalCancer #Cancer
Like Comment
To view or add a comment, sign in
Cancers MDPI

4,511 followers
3mo
Report this post
📜Today we share the #Review "The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance" 🧐by Mary Abdelmalak et al. Access the full paper here👉 https://lnkd.in/d6VcntUS Keywords: abemaciclib; advanced breast cancer; CDK4/6 inhibitor
Like Comment
To view or add a comment, sign in
Yüksel ÜRÜN

Prof.Dr. Ankara University School of Medicine, Department of MEdical Oncology
10mo
Report this post
Exciting results from the phase 1 study of divarasib (#GDC6036), a potent KRAS G12C inhibitor, are in! 🎉 🎯Durable responses seen in various solid tumors, including non-small-cell lung cancer (ORR 53.4% and PFS: 13.1 months) & colorectal cancer (ORR 29% and PFS: 5.6 months). 🎯Low-grade side effects & promising outcomes. #CancerResearch #LungCancer @NEJM @OncoAlert @medpagetoday @OncBrothers DOI: 10.1056/NEJMoa2303810

Yüksel Ürün on X

twitter.com
Like Comment
To view or add a comment, sign in
Luigi Fontana, MD, PhD, FRACP

Professor & Ullmann (Picasso) Chair of Translational Metabolic Health | Scientific Director, Charles Perkins Centre RPA Clinic & Healthy Longevity Program at Sydney University | Author & Environmentalist | Views my own.
4mo
Report this post
In this large US cohort with historical air pollutant exposure estimates, PM2.5 was associated with risk of estrogen receptor–positive breast cancer. A 10 ug/m3 increase in PM2.5 was statistically significantly associated with overall breast cancer incidence (HR = 1.08, 95% CI = 1.02 to 1.13). The association was evident for estrogen receptor–positive (HR = 1.10, 95% CI = 1.04 to 1.17) but not estrogen receptor–negative tumors (HR = 0.97, 95% CI = 0.84 to 1.13; Pheterogeneity = .3). https://lnkd.in/gUZkibeY
Like Comment
To view or add a comment, sign in